Medical Oncology

ROS1+

Questions discussed in this category

What is your preferred first line therapy for ROS1 rearranged metastatic NSCLC without CNS mets?

How do you decide between entrectinib or crizotinib? Since no head-to-head comparison, can real-world datasets (such as Doebele et al., Journal of Cli...

5 Answers available

Can immunotherapy, alone or with chemo, be considered for ROS1+ NSCLC after exhausting ROS1 targeted therapy options?

4 Answers available

How would you approach metastatic adenocarcinoma of the lung with ROS1 rearrangement by FISH and EGFR mutation by NGS?

4 Answers available

What would you use as next line of treatment for a patient with ROS1+ metastatic NSCLC progressing on first line TKI?

If starting with entrectinib would you still try crizotinib, or move to lorlatinib or another novel TKI? Or change entirely to chemotherapy, immunothe...

3 Answers available

Are there specific ROS1 fusions/mutations that confer sensitivity or resistance to therapy to help guide treatment selection in first line or at progression?

3 Answers available

What is your preferred first line therapy for ROS-1 rearranged metastatic NSCLC for patients presenting with CNS metastases?

1 Answer available

Papers discussed in this category

N Engl J Med, 2014 Sep 27

Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-09-15

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

J. Clin. Oncol., 2018 Mar 29

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

Cancer discovery, 2017-04

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

JAMA, 2014-05-21

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

The New England journal of medicine, 2018-06-14

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

J Thorac Oncol, 2016 Apr 16

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.

J Thorac Oncol, 2018 Jun 05

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.

J Clin Oncol, 2021 Mar 01

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-11

The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.

Related Topics in Medical Oncology